In the critical and consistently high-demand field of gynecology, products that offer comprehensive and convenient treatment solutions are highly valued. Fucoziff AS Kit, with its strategic combination of Fluconazole (150mg), Azithromycin (1000mg), and Secnidazole (1000mg), is a best-in-class product for the syndromic management of common vaginal and sexually transmitted infections. As a PCD pharma company, we recognize the consistent, high demand for such a practical and effective product, making it a valuable asset for any pharma distributor or wholesaler.
-
Fluconazole: A potent antifungal that targets and eliminates yeast infections.
-
Azithromycin: A powerful antibiotic that combats various bacterial pathogens.
-
Secnidazole: A proven antiprotozoal and antibacterial agent.
The "kit" format is a significant advantage, as it ensures that patients receive and take all the necessary medications as prescribed, thereby improving treatment outcomes and patient compliance. This makes Fucoziff AS Kit a highly recommended product by gynecologists and a stable, high-demand product for the market.
At Cafoli Lifecare, we are committed to providing our B2B pharma partners with high-quality, profitable products. Our Fucoziff AS Kit is manufactured under strict quality controls and comes with a competitive pricing structure. By partnering with us, you gain access to a reliable supply of this essential medication and the comprehensive support needed to succeed in the wholesale pharma market. Choose this product to build a strong and reputable business in the gynecology segment.
Common side effects of Terifix Injection may include nausea, leg cramps, dizziness, headache, and pain at the injection site. Some patients may also experience transient increases in calcium levels shortly after administration. Rare but serious side effects include orthostatic hypotension, especially after the first few doses, and very rarely, prolonged use has been associated with an increased risk of osteosarcoma in animal studies. However, this risk in humans is extremely low when used as recommended.
Terifix Injection is indicated for the treatment of osteoporosis in postmenopausal women, men at high risk of fracture, and patients with glucocorticoid-induced osteoporosis who are at increased risk for bone fractures. It contains Teriparatide, a recombinant form of human parathyroid hormone (PTH 1-34), which helps stimulate new bone formation, increases bone mineral density (BMD), and reduces the risk of vertebral and non-vertebral fractures. It is especially recommended in patients who have failed or are intolerant to previous osteoporosis treatments.
Terifix Injection is typically administered as a once-daily subcutaneous injection in the thigh or abdomen, under the guidance of a healthcare provider. The total treatment duration should not exceed 24 months over a patient’s lifetime. Regular monitoring of calcium levels, renal function, and vitamin D status is advised during treatment. Terifix is not recommended in patients with bone malignancies, Paget’s disease, hypercalcemia, or those who have received radiation therapy to bones. Patients should remain seated or lying down for a few minutes after administration to reduce the risk of dizziness or fainting.
Store Terifix Injection in a refrigerator at 2°C to 8°C. Do not freeze. Keep the pen/cartridge tightly closed when not in use and protect it from direct light. Once opened, the multi-dose pen can typically be used for up to 28 days, as per manufacturer’s instructions. Always keep it out of reach of children, and dispose of needles properly after use.